QUORUM

Quantum Genomics Raises a Gross Amount of Approximately € 15 M

Retrieved on: 
Tuesday, April 26, 2022
IDMC, Heart failure, Risk, Research, GLOBE, Patient, Mass meeting, Director, Paris Descartes University, General officer, Hope, Bookrunner, Annual general meeting, Head, Euronext Growth, COVID-19, Commonwealth, Deal, Genomics, Company, Cardiovascular disease, Shareholder, CEO, Board, FRESH, Quantum, Hypertension, Commercial code, ISIN, Julphar, Safety, Growth, Person, Greater Manchester Transport Innovation Fund, Agency, Brain, Rale, QUORUM, Security (finance), Pharmaceutical industry, Microscope, Medical device, Management, Insurance, Holding company, Phase

It will also allow Quantum Genomics to reinforce and broaden their shareholding structure.

Key Points: 
  • It will also allow Quantum Genomics to reinforce and broaden their shareholding structure.
  • This represents an increased focus by Quantum Genomics and Julphars on their cooperation to market firibastat in the Middle East, Africa, some member countries of the Commonwealth of Independent States and Turkey.
  • Any decision to subscribe for or purchase Quantum Genomics shares should be made solely on the basis of public information about Quantum Genomics.
  • Quantum Genomics is a biopharmaceutical company specializing in the development of a new class of cardiovascular drugs, based on the Brain Aminopeptidase A Inhibition (BAPAI) mechanism.

Aldel Financial Inc. Reminds Stockholders TO VOTE PRIOR TO The Special Meeting on December 1, 2021

Retrieved on: 
Tuesday, November 16, 2021
Professional Services, Finance, Tax, Prospectus, Security (finance), Growth, COVID-19, THE, Communication, Meeting, Risk, Eastern Time Zone, Ownership, Failure, QUORUM, Telephone, Securities Act of 1933, Forward-looking statement, U.S. Securities and Exchange Commission, Business architecture, New York Stock Exchange, Mergers and acquisitions, Private Securities Litigation Reform Act, MET, Special, Illinois, LLC, Sale, DOES, SEC, Proxy, Interest on Lawyer Trust Accounts, ADF, Name, Combination, PIPE, Bank account, File, Sub, NYSE, Holding company

WHETHER OR NOT YOU CHOOSE TO REDEEM YOUR SHARES, THE COMPANY IS ASKING YOU TO PLEASE VOTE.

Key Points: 
  • WHETHER OR NOT YOU CHOOSE TO REDEEM YOUR SHARES, THE COMPANY IS ASKING YOU TO PLEASE VOTE.
  • Every stockholder's vote is important, regardless of the number of shares you hold.
  • Voting either FOR or AGAINST the proposals on the proxy card will not affect your right to redeem your shares.
  • Stockholders holding common stock at the close of business on November 9, 2021 are entitled to vote at the Meeting.

Quantum Genomics Presents Results from Phase IIb QUORUM Study of Firibastat in Heart Failure at the European Society of Cardiology Meeting

Retrieved on: 
Friday, August 27, 2021
European Society of Cardiology, INSERM, Population, Blood pressure, Myocardial infarction, Genomics, Scientific Centre of Monaco, Angiotensin, BID, GLOBE, Phase, Biomarker, Medical research, Inserm, Magnetic resonance, National Research Corporation, Paris Descartes University, Hyperkalemia, Heart, IIB, Pathology, Kidney failure, Hypertension, Safety, QUORUM, ESC, Patient, ACE, CEO, Euronext Growth, MRI, Angioedema, III, Brain, CNRS, Heart failure, Medical device, Pharmaceutical industry, Phosphorus

The QUORUM study demonstrates the efficacy and good safety profile of firibastat.

Key Points: 
  • The QUORUM study demonstrates the efficacy and good safety profile of firibastat.
  • In severe patients with an ejection fraction less than 50%, firibastat appears to be more effective than ramipril.
  • For this reason, QUORUMs phase IIb results pave the way for a phase III clinical study in severe patients whose protocol will be finalized with a selected partner pharmaceutical company.
  • Highlights from the phase IIb QUORUM study are included below:
    295 patients were enrolled in the study within 24 hours of a first myocardial infarction.